imiquimod has been researched along with baicalin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chen, Y; Li, X; Song, S; Wang, Y; Zhu, J | 1 |
2 other study(ies) available for imiquimod and baicalin
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Potential mechanism of oral baicalin treating psoriasis via suppressing Wnt signaling pathway and inhibiting Th17/IL-17 axis by activating PPARĪ³.
Topics: Animals; Disease Models, Animal; Estrogens; Flavonoids; Imiquimod; Interleukin-17; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; PPAR gamma; Protein Kinases; Psoriasis; Skin; Skin Diseases; Th17 Cells; Tumor Necrosis Factor-alpha; Wnt Signaling Pathway | 2022 |